

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Diagnostics Assessment Programme

Molecular testing for Lynch syndrome in people with colorectal cancer

Provisional stakeholder list

Manufacturer(s)
Manufacturer(s) of related technologies (not included in scope) Promega UK Ltd Roche Diagnostics UK Ltd BIOCARTIS
Professional groups British Society of Gastroenterology Cancer Genetics Group Royal College of Nursing Royal College of Pathologists Royal College of Physicians
Patient/carer groups Bowel Cancer UK Genetic Alliance Lynch syndrome UK
Research groups
Associated guideline groups
Provider of NHS services Bristol Genetics Laboratory Manchester Centre for Genomic Medicine Manchester Royal Infirmary Northern Molecular Genetics Service Oxford Radcliffe Hospitals NHS Foundation Trust Sheffield Diagnostic Genetics Service
External Assessment Group PenTAG
Others Cardiff and Vale University Health Board Department of Health Healthcare Improvement Scotland NETSCC NHS England

Definitions:Stakeholders

Individuals or organisations interested in a topic being evaluated by the Diagnostics Assessment Programme, and who register to become a stakeholder. For example, manufacturers of the technology, national organisations that represent healthcare professions who operate or use the results of the technology, national patient or carer organisations, NHS service providers and commissioners, statutory organisations and research organisations.

External Assessment Group (EAG)

An independent academic group commissioned by the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) that prepares a systematic review of the clinical and cost effectiveness of the technology(ies).